| Objective:To evaluate the efficacy and toxicity of combination of docetaxel,oxaliplatin and5-fluorouracil in patients with advanced gastric cancer.Methods:Forty-one advanced gastric cancer patients who received docetaxel,oxaliplatin and5-fluorouracil combination regimen during2004-2010were analyzed retropectively.Docetaxel75mg·m-2(d1),oxaliplatin130mg·m-2(d2)and fluorouracil400-500mg· m-2(d2-6) in21-day cycle for at least2cycles.The statistical analysis is performed by SPSS17.0.Results The outcomes of the regimen were as follows:overall response rate (OPR)26.8%, disease control rate (DCR)78.0%, With median follow-up13months,median progression-free survival (mPFS)5.6months(95%CI3.52～7.6months), median overall survival (mOS)12.3months (95%CI2.7-21.9months).1-year and2-year survival rates were46.3%and21.9%,respectively.The most common adverse effects were bone marrow suppression(mainly leucopenia and neutropenia),gastro-intestinal toxicity(nausea and vomitting), the incidences were73.2%and68.3%,respectively. Diarrhea,alopecia and neurotoxicity were also noted in a few patients. Multivariate analysis analysis showed that the response to the regimen and serum level of CA199were independent prognostic factors for PFS of patients with advanced gastric cancer, the response to the regimen was alse an independent prognostic factors for OS.Conclusion The combination regimen of docetaxel,oxaliplatin and5-fluorouracil can be effectively and safely applied to advanced gastric cancer patients. The response to the regimen and serum level of CA199were independent prognostic factors for PFS of patients with advanced gastric cancer, the response to the regimen was alse an independent prognostic factor for OS. |
PDF Full Text Request